{"nctId":"NCT01509612","briefTitle":"Additive Homeopathy in Cancer Patients","startDateStruct":{"date":"2012-02-01","type":"ACTUAL"},"conditions":["Malignant Tumors"],"count":150,"armGroups":[{"label":"Additive homeopathy in cancer patients","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Additive classical homeopathy"]},{"label":"Additive homeopathic placebo globules","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Homeopathic Placebo globules"]},{"label":"No intervention","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"Additive classical homeopathy","otherNames":["Classical homeopathic remedies"]},{"name":"Homeopathic Placebo globules","otherNames":["Homeopathic Placebo globules looking identical to verum"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Informed consent\n* Clinical diagnosis of advanced tumor stages of non small-cell lung carcinoma (NSCLC) IIIB, IIIC, IV.\n\nExclusion Criteria:\n\n* sensitizing mutation of the EGFR gene or translocation of the ALK gene\n* refusal to sign informed consent\n* pregnancy\n* hematological, hepatic, or renal pathology\n* coronary heart disease\n* history of secondary tumor\n* major surgery within 4 weeks prior to study entry\n* active infection and symptomatic peripheral neuropathy\n* central nervous system metastases unless the metastases were treated and stable\n* active autoimmune disease\n* use of systemic immunosuppressive treatment\n* use of systemic treatment during the previous 2 years\n* active interstitial lung disease, or a history of pneumonitis for which glucocorticoids were prescribed\n* previous systemic therapy for metastatic disease or previous irradiation\n* use of any complementary and/or alternative therapy, including homeopathy other than the research treatment during the trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"EORTC-QLQ-C30 Score","description":"Quality of life was evaluated by using the Global Health Status assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC-QLQ-C30), which was completed by participants throughout the study.\n\nThe score of the scale ranges from 0-100, where high values mean good health status, while lower values indicate poor health status.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.2","spread":"28.0"},{"groupId":"OG001","value":"46.6","spread":"25.8"}]}]}]},{"type":"SECONDARY","title":"Survival","description":"Survival was assessed by chart review, at every study visit (every 9 weeks throughout the trial), and by information of the central mortality registry of Austria","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":47},"commonTop":[]}}}